tbc-11251 has been researched along with Kidney Failure, Chronic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dhaun, N; Goddard, J; Haughie, S; Johnston, NR; Kerr, D; MacIntyre, IM; Melville, V; Webb, DJ | 1 |
| Dhaun, N; Goddard, J; Johnston, NR; Webb, DJ | 1 |
| Kohan, DE; Pollock, DM | 1 |
1 review(s) available for tbc-11251 and Kidney Failure, Chronic
| Article | Year |
|---|---|
Endothelin antagonists for diabetic and non-diabetic chronic kidney disease.
Topics: Animals; Clinical Trials as Topic; Diabetic Nephropathies; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Humans; Isoxazoles; Kidney Failure, Chronic; Pyridines; Pyrimidines; Renal Dialysis; Renal Insufficiency, Chronic; Thiophenes; Treatment Outcome | 2013 |
2 trial(s) available for tbc-11251 and Kidney Failure, Chronic
| Article | Year |
|---|---|
Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease.
Topics: Adult; Antihypertensive Agents; Arteries; Blood Pressure; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Female; Glomerular Filtration Rate; Humans; Hypertension; Isoxazoles; Kidney Failure, Chronic; Male; Middle Aged; Nifedipine; Proteinuria; Radioimmunoassay; Thiophenes; Treatment Outcome; Vascular Resistance; Vasodilator Agents | 2011 |
Chronic selective endothelin A receptor antagonism reduces serum uric acid in hypertensive chronic kidney disease.
Topics: Cross-Over Studies; Double-Blind Method; Endothelin A Receptor Antagonists; Hypertension; Hyperuricemia; Isoxazoles; Kidney Failure, Chronic; Thiophenes; Treatment Outcome; Uric Acid | 2011 |